



Modern Evaluation and Treatment of Malignant Pancreatic, Liver and Biliary Tract Tumours

Guest Editor:

Dr. Adam Frampton

Department of Clinical and Experimental Medicine, Faculty of Health, University of Surrey, Guildford GU2 7WG, UK

Deadline for manuscript submissions:

closed (20 December 2023)

Message from the Guest Editor


Pancreatic ductal adenocarcinoma (PDAC) and liver and biliary tract tumours (including ampullary cancer, gallbladder cancer, and cholangiocarcinoma) are aggressive malignancies. Most patients present with advanced disease due to late diagnosis, and as there are few effective therapeutic options, outcomes are extremely poor.

To improve survival, efforts must be multifaceted and focus on prevention, early identification of high-risk individuals, and prompt diagnosis, as well as molecular-based targeted therapies for established disease.

In this Special Issue, we are inviting original research articles, reviews, and perspectives to address some of these challenges for these tumours. Topics will include but are not limited to the biology and genomic characteristics of these cancers; the coding and non-coding transcriptome; the role of extracellular vesicles; biomarkers in tissue, blood, and biofluids; “liquid biopsies”; the identification of novel therapeutic targets; and new surgical/oncological/radiological approaches for treating localized and more advanced disease.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)